Sana Biotechnology, Inc. $SANA Stake Lifted by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC increased its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 125.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,564 shares of the company’s stock after acquiring an additional 22,005 shares during the period. Pallas Capital Advisors LLC’s holdings in Sana Biotechnology were worth $108,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in SANA. Northern Trust Corp boosted its holdings in shares of Sana Biotechnology by 5.3% in the fourth quarter. Northern Trust Corp now owns 1,188,346 shares of the company’s stock valued at $1,937,000 after acquiring an additional 60,004 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Sana Biotechnology by 287.2% in the fourth quarter. Jane Street Group LLC now owns 367,855 shares of the company’s stock valued at $600,000 after acquiring an additional 272,862 shares in the last quarter. Ameriprise Financial Inc. bought a new position in shares of Sana Biotechnology in the fourth quarter valued at approximately $29,000. BNP Paribas Financial Markets acquired a new stake in Sana Biotechnology during the fourth quarter valued at approximately $34,000. Finally, Bank of America Corp DE lifted its stake in Sana Biotechnology by 11.3% during the fourth quarter. Bank of America Corp DE now owns 1,131,813 shares of the company’s stock valued at $1,845,000 after purchasing an additional 115,347 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

SANA has been the subject of several recent research reports. Morgan Stanley initiated coverage on shares of Sana Biotechnology in a research note on Thursday, July 3rd. They set an “overweight” rating and a $12.00 target price for the company. JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $8.00.

Sana Biotechnology Stock Up 5.2%

Shares of SANA opened at $3.25 on Tuesday. The company’s fifty day moving average is $3.63 and its 200-day moving average is $2.74. Sana Biotechnology, Inc. has a 12 month low of $1.26 and a 12 month high of $7.30. The firm has a market cap of $772.88 million, a price-to-earnings ratio of -3.07 and a beta of 1.88.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. As a group, research analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.